NanoViricides, Inc. (NYSE American: NNVC) has initiated patient enrollment and dosing in its Phase II clinical trial of NV-387 Oral Gummies for the treatment of Bundibugyo Ebolavirus and other Ebola viruses, the company announced. The trial is taking place at an Ebola Treatment Center in the Ituri province of the Democratic Republic of Congo (DRC). The Phase IIA portion began enrollment and dosing around Sept. 23. This marks a significant milestone for the clinical-stage company, which is developing a novel class of broad-spectrum antiviral drugs.
The Phase IIA portion is designed to establish a safe and well-tolerated dosing protocol for NV-387. The resulting protocol will then be used in the Phase IIB portion, which will evaluate safety, tolerability, and effectiveness. The trial is registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077. For investors and stakeholders, this development underscores the potential of NanoViricides’ platform technology to address high-consequence viral pathogens.
NanoViricides is creating special purpose nanomaterials for antiviral therapy, and its lead drug candidate NV-387 is a broad-spectrum antiviral that the company plans to develop for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company’s novel nanoviricide class of drug candidates is based on intellectual property and technology from TheraCour Pharma, Inc. The company holds broad, exclusive, sub-licensable field licenses for several antiviral applications. More details about the company and its pipeline are available at www.nanoviricides.com.
The Ebola trial is part of NanoViricides’ broader strategy to develop treatments for a range of viral diseases, including oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola. The company’s platform technology is based on the TheraCour nanomedicine technology, licensed from TheraCour and AllExcel. NanoViricides holds a worldwide exclusive perpetual license for several drugs targeting specific human viral diseases, including Ebola/Marburg viruses. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC.
MissionIR, a specialized communications platform, distributed the announcement. MissionIR is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit MissionIR. The implications of this trial are significant: if successful, NV-387 could become a much-needed oral treatment for Ebola, a disease with high mortality rates and limited therapeutic options, potentially improving outbreak response in resource-limited settings. For NanoViricides, positive results could validate its nanoviricide platform and open doors for further development across multiple viral indications.
